186 related articles for article (PubMed ID: 38602775)
1. Minnelide suppresses GVHD and enhances survival while maintaining GVT responses.
Copsel SN; Garrido VT; Barreras H; Bader CS; Pfeiffer B; Mateo-Victoriano B; Wolf D; Gallardo M; Paczesny S; Komanduri KV; Benjamin CL; Villarino AV; Saluja AK; Levy RB
JCI Insight; 2024 Apr; 9(9):. PubMed ID: 38602775
[TBL] [Abstract][Full Text] [Related]
2. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft-versus-host disease by inhibiting T-cell migration to the gastrointestinal tract.
Tsubokura Y; Yoshimura H; Satake A; Nasa Y; Tsuji R; Ito T; Nomura S
Immun Inflamm Dis; 2022 Sep; 10(9):e688. PubMed ID: 36039651
[TBL] [Abstract][Full Text] [Related]
3. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical evaluation of Minnelide as a therapy for acute myeloid leukemia.
Giri B; Gupta VK; Yaffe B; Modi S; Roy P; Sethi V; Lavania SP; Vickers SM; Dudeja V; Banerjee S; Watts J; Saluja A
J Transl Med; 2019 May; 17(1):163. PubMed ID: 31109340
[TBL] [Abstract][Full Text] [Related]
5. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model.
Makuuchi Y; Nakashima Y; Nishimoto M; Koh H; Hino M; Nakamae H
Exp Hematol; 2023 Jul; 123():56-65. PubMed ID: 37098360
[TBL] [Abstract][Full Text] [Related]
6. Improved NK Cell Recovery Following Use of PTCy or Treg Expanded Donors in Experimental MHC-Matched Allogeneic HSCT.
Wolf D; Barreras H; Copsel SN; Komanduri KV; Levy RB
Transplant Cell Ther; 2022 Jun; 28(6):303.e1-303.e7. PubMed ID: 35302008
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
[TBL] [Abstract][Full Text] [Related]
8. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
10. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
11. Defibrotide combined with triple therapy including posttransplant cyclophosphamide, low dose rabbit anti-t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood stem cell transplantation for hematologic malignancies.
Akpinar S; Kayikci O; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103367. PubMed ID: 35120825
[TBL] [Abstract][Full Text] [Related]
12. Alloantigen expression on malignant cells and healthy host tissue influences graft-versus-tumor reactions after allogeneic hematopoietic stem cell transplantation.
Robert S; Albring JC; Frebel K; Opitz C; Urh J; Wolf C; Heinrich C; Berdel WE; Stelljes M
Bone Marrow Transplant; 2018 Jul; 53(7):807-819. PubMed ID: 29362503
[TBL] [Abstract][Full Text] [Related]
13. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
15. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.
Barreras H; Copsel SN; Bader CS; Ding Y; Wolf D; Cash C; Stacey CJ; Benjamin C; Seavey MM; Wolf J; Jasuja RR; Pfeiffer B; Hill GR; Komanduri KV; Jurecic R; Malek TR; Levy RB
Transplant Cell Ther; 2023 May; 29(5):341.e1-341.e9. PubMed ID: 36804930
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
19. Post-Transplantation Cyclophosphamide Uniquely Restrains Alloreactive CD4
Hadjis AD; Nunes NS; Khan SM; Fletcher RE; Pohl AP; Venzon DJ; Eckhaus MA; Kanakry CG
Front Immunol; 2022; 13():796349. PubMed ID: 35242129
[TBL] [Abstract][Full Text] [Related]
20. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
